GLP-1 Weight-Loss Drug Regulations Tighten: Shanghai Pharmacies Now Require Physical Prescriptions

China’s approach to GLP-1 medications just got way stricter.

On May 14, 2026, The Paper (Pengpai Xinwen 澎湃新闻) reported that Shanghai (Shanghai 上海) pharmacies were implementing a major policy shift.

Starting May 15, weight-loss drugs like Semaglutide and Tirzepatide would require valid physical paper prescriptions from hospitals (yiyuan 医院) for purchase.

This isn’t just a casual suggestion—it’s a game-changer for how these drugs are distributed across the country’s biggest cities.

—

The New Rules: What Changed & Why It Matters

Here’s what’s actually happening on the ground:

• Internet hospital prescriptions are no longer accepted—even though pharmacies previously had the authority to issue them.
• Some pharmacy staff received notifications as early as May 13, meaning the mandate came into effect immediately on May 14 for certain locations.
• Physical prescriptions must be within a three-day validity period—expired scripts won’t work, period.
• Drug names, dosages, and specifications must match exactly between the prescription and what you’re buying.

Example: If your doctor writes Semaglutide, you can’t just swap it for Tirzepatide at the counter.

One pharmacy staff member was blunt about the reasoning: “It is mainly for control, to prevent people from buying and injecting these drugs haphazardly.”

—

Why the Crackdown? The Legal Framework Behind It

This regulatory tightening isn’t random.

It’s directly tied to the “Implementation Regulations of the Drug Administration Law of the People’s Republic of China” (Zhonghua Renmin Gongheguo Yaopin Guanli Fa Shishi Tiaoli 中华人民共和国药品管理法实施条例), which takes effect on May 15, 2026.

The key regulation?

Drug retail enterprises must sell prescription drugs only upon presentation of a valid prescription.

That’s it. That’s the law.

—

E-Commerce: The Wild West Still Exists (For Now)

Here’s where things get interesting.

While offline pharmacies tightened security, e-commerce platforms remain relatively unrestricted for GLP-1 medications.

According to the “List of Drugs Prohibited for Online Sales (First Edition)” released in November 2022, most injections are banned from online retail—with one notable exception: anti-diabetic medications.

On May 14, reporters tested several e-commerce platforms and found something revealing:

• Physical prescriptions are not yet mandatory for online purchases of GLP-1 drugs.
• Some platforms prompt users to upload a prescription, but it remains completely optional.
• Users can successfully place orders by selecting specific medical conditions from a dropdown menu.

—

The Loophole: How People Are Actually Gaming the System

This is where the regulatory gap becomes obvious.

Originally, GLP-1 drugs were designed to treat Type 2 diabetes.

They became viral because they also cause significant weight loss—which is why everyone and their neighbor is trying to buy them for cosmetic reasons.

Here’s the clever workaround that exists on e-commerce platforms:

• “Simple obesity” is NOT listed as a purchasable condition on most platforms.
• Instead, buyers can select from legitimate-sounding options:
  • Type 2 diabetes
  • General diabetes
  • Hyperglycemia combined with being overweight
• People successfully place orders by selecting one of these conditions, even if they don’t actually have diabetes.

It’s a work-around, not a solution. And it’s exactly why regulations are tightening.

—

Regional Enforcement: Jiangxi Takes It Further

Shanghai isn’t the only region cracking down.

On May 8, 2026, the Jiangxi Provincial Drug Administration (Jiangxisheng Yaopin Jiandu Guanliju 江西省药品监督管理局) issued the “Notice on Further Strengthening the Supervision of the Circulation of Semaglutide and Tirzepatide.”

This notice was effective immediately and mandates stricter controls:

• Retail enterprises must implement strict prescription drug management.
• These drugs can only be sold with a real, valid prescription from a licensed physician.
• Selling without a prescription is strictly prohibited.
• Verification of prescriptions is mandatory before sale.
• “Selling first and supplementing the prescription later” is banned—a practice that was apparently common enough to warrant specific mention.

—

E-Commerce Enforcement: What Platforms Must Do

The Jiangxi notice also lays out specific requirements for online platforms:

• Platforms must use technical means to establish strict keyword filtering mechanisms.
• Product listing review processes must be routine for high-risk injections and prescription drugs.
• Semaglutide and Tirzepatide must undergo regular inspections.
• Platforms cannot sell these drugs without proper retail qualifications.
• State-restricted formulations cannot be sold.
• Upon discovering violations, platforms must:
  • Immediately delist the products
  • Ban the shops selling them
  • Report to local drug regulatory authorities

—

The Bigger Picture: Why This Matters

On the surface, this is about controlling weight-loss drug abuse.

But it’s actually about something more fundamental.

Industry analysts explained the reasoning to reporters:

“Due to their weight-loss efficacy, GLP-1 drugs have become high-demand consumer items. However, fundamentally, these are strictly controlled prescription drugs with specific indications, contraindications, and potential adverse reactions. They must be used under professional guidance after a doctor evaluates the patient’s physical condition and determines the appropriate dosage and course of treatment.”

Translation: These aren’t candy.

GLP-1 medications have real side effects, drug interactions, and health considerations that require professional medical oversight.

—

The Regulatory Goals

Here’s what the government is actually trying to accomplish:

• Eliminate the sale of drugs without prescriptions in offline pharmacies.
• Guide the public to view GLP-1 drugs rationally instead of as a cosmetic quick-fix.
• Prevent abuse and misuse of these medications.
• Ensure compliant, safe, and rational use of GLP-1 medications across the market.

—

What This Means for the Market

The GLP-1 drug market in China is in transition.

Offline channels are becoming more restrictive and controlled.

E-commerce channels still have gaps, but enforcement is clearly coming next.

For investors, founders, and marketers watching this space: the era of easy access to weight-loss drugs is ending.

The future of the GLP-1 market in China will be shaped by how platforms and pharmacies adapt to these new regulations—and how quickly e-commerce enforcement catches up to retail restrictions.

—

References

• Weight-loss drug sales policy tightened? Starting tomorrow, Shanghai retail pharmacies require paper prescriptions from hospitals – The Paper (Pengpai Xinwen)
• Implementation Regulations of the Drug Administration Law – National Medical Products Administration
• Notice on Strengthening Supervision of Semaglutide Circulation – Jiangxi Provincial Drug Administration